Galmed Pharmaceuticals Ltd (GLMD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Galmed Pharmaceuticals Ltd (GLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9441
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company. The company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd (GLMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11
Partnerships 12
Galmed Pharma Enters into Agreement with University of California 12
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13
Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14
Licensing Agreements 15
Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15
Equity Offering 16
Galmed Pharma Prices Public Offering of Shares for USD75 Million 16
Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18
Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19
Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20
Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21
Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22
One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23
Galmed Pharma Completes IPO For US$44 Million 24
Galmed Pharmaceuticals Ltd – Key Competitors 26
Galmed Pharmaceuticals Ltd – Key Employees 27
Galmed Pharmaceuticals Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 05, 2018: Galmed Pharmaceuticals provides business update and reports third quarter 2018 financial results 29
May 09, 2018: Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results 30
Nov 09, 2017: Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 31
Jul 31, 2017: Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 32
May 15, 2017: Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results 33
Mar 23, 2017: Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 34
Corporate Communications 36
Jun 08, 2017: Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors 36
Legal and Regulatory 37
Feb 07, 2018: Galmed Granted “Preferred Technological Enterprise” Status Which may Provide the Company With Significant Financial Benefits 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11
Galmed Pharma Enters into Agreement with University of California 12
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13
Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14
Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15
Galmed Pharma Prices Public Offering of Shares for USD75 Million 16
Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18
Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19
Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20
Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21
Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22
One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23
Galmed Pharma Completes IPO For US$44 Million 24
Galmed Pharmaceuticals Ltd, Key Competitors 26
Galmed Pharmaceuticals Ltd, Key Employees 27
Galmed Pharmaceuticals Ltd, Subsidiaries 28

List of Figures
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Galmed Pharmaceuticals Ltd (GLMD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TechnipFMC Plc (FTI):企業の財務・戦略的SWOT分析
    TechnipFMC Plc (FTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Schweitzer Engineering Laboratories Inc:企業の戦略的SWOT分析
    Schweitzer Engineering Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Ushdev International Limited (511736):企業の財務・戦略的SWOT分析
    Ushdev International Limited (511736) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • CIRCOR International Inc (CIR):石油・ガス:M&Aディール及び事業提携情報
    Summary CIRCOR International Inc (CIRCOR) is an industrial equipment company that designs, manufactures, and markets flow control solutions and engineered products and sub-systems. Its product offerings include integrated flow control solutions, high pressure pneumatic systems, valves, actuation, sw …
  • Anthelio Healthcare Solutions Inc.-医療機器分野:企業M&A・提携分析
    Summary Anthelio Healthcare Solutions Inc. (Anthelio), formerly PHNS Inc., is a healthcare IT service company that offers information technology and business process services to hospitals, physician practice groups and other healthcare providers. The company’s suite of software solutions include int …
  • The Vanguard Group Inc:企業の戦略的SWOT分析
    The Vanguard Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ensco plc:企業の戦略・SWOT・財務情報
    Ensco plc - Strategy, SWOT and Corporate Finance Report Summary Ensco plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Nippon Suisan Kaisha, Ltd.:企業の戦略・SWOT・財務分析
    Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Rex Energy Corp (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds pro …
  • Anadolubank A.S.:企業の戦略・SWOT・財務情報
    Anadolubank A.S. - Strategy, SWOT and Corporate Finance Report Summary Anadolubank A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hokkaido Electric Power Co Inc (9509):企業の財務・戦略的SWOT分析
    Hokkaido Electric Power Co Inc (9509) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Mustek Limited (MST):企業の財務・戦略的SWOT分析
    Mustek Limited (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Faisal Islamic Bank of Egypt (SAE):企業の戦略的SWOT分析
    Faisal Islamic Bank of Egypt (SAE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ichibanya Co Ltd:企業の戦略・SWOT・財務分析
    Ichibanya Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ichibanya Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • DIA Imaging Analysis Ltd-医療機器分野:企業M&A・提携分析
    Summary DIA Imaging Analysis Ltd (DIA Imaging Analysis), formerly DiACardio Ltd is a healthcare technology company that offers medical imaging analysis software solutions. The company’s products comprise LVivo SWM, LVivo EF, and LVivo Strain. DiACardio’s LVivo SWM is a fully automated echo device or …
  • Asatsu-DK Inc.:企業の戦略的SWOT分析
    Asatsu-DK Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Al Rajhi Banking & Investment Corp (1120):企業の財務・戦略的SWOT分析
    Al Rajhi Banking & Investment Corp (1120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • Thor Mining Plc (THR):企業の財務・戦略的SWOT分析
    Summary Thor Mining Plc (Thor Mining) is a mining and mineral exploration and development company. The company carries out acquisition, exploration and develops gold, tungsten and molybdenum properties. Its projects include Molyhil Tungsten and Molybdenum, Spring Hill Gold, Dundas Gold project, and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆